Spyre Therapeutics

Yahoo Finance • 19 hours ago

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational t... Full story

Yahoo Finance • 2 days ago

Spyre Therapeutics launches $300M public stock offering

* Spyre Therapeutics (SYRE [https://seekingalpha.com/symbol/SYRE]) has started a $300M underwritten public offering [https://seekingalpha.com/pr/20471165-spyre-therapeutics-announces-proposed-public-offering-of-its-common-stock] of commo... Full story

Yahoo Finance • 2 days ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational t... Full story

Yahoo Finance • 2 days ago

Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis Results

Spyre Therapeutics stock soared to a four-year high Monday on positive 12-week test results for its ulcerative colitis treatment. Continue Reading... Full story

Yahoo Finance • 7 days ago

Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears

Cameron Turtle, the chief executive officer of Spyre Therapeutics(NASDAQ:SYRE), reported the direct sale of 15,000 shares of common stock for approximately $740K on April 1, 2026, according to a SEC Form 4 filing. Transaction summary Met... Full story

Yahoo Finance • 12 days ago

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the sta... Full story

Yahoo Finance • 28 days ago

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools

Key Points VR Adviser, LLC added 1,000,000 shares of Spyre Therapeutics; estimated trade size is $25.78 million (based on quarterly average pricing). The quarter-end value of the position increased by $75.73 million, reflecting both tradi... Full story

Yahoo Finance • 28 days ago

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down

On February 17, 2026, VR Adviser, LLC disclosed in a U.S. Securities and Exchange Commission filing that it sold 5,845,915 shares of Ocular Therapeutix(NASDAQ:OCUL), an estimated $71.01 million trade based on quarterly average pricing. VR... Full story

Yahoo Finance • last month

VR Adviser Adds Over 1 Million Savara Shares

According to a filing with the Securities and Exchange Commission dated Feb. 17, VR Adviser, LLC increased its position in Savara(NASDAQ:SVRA) by 1,059,332 shares during the fourth quarter. The fund’s Savara stake ended the quarter valued... Full story

Yahoo Finance • 2 months ago

Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026

Spyre Therapeutics (NASDAQ:SYRE) is one of the 17 biotechnology stocks with more than 50% upside. As of the close of play on February 12, consensus sentiment around Spyre Therapeutics (NASDAQ:SYRE) was strongly bullish. The stock had rece... Full story

Yahoo Finance • 5 months ago

Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003

​Spyre Therapeutics, Inc. (NASDAQ:SYRE) is one of the Hottest Small Cap Stocks to Buy Now. On November 4, Spyre Therapeutics, Inc. (NASDAQ:SYRE) announced positive interim Phase 1 results for SPY003, which is its novel, half-life extended... Full story

Yahoo Finance • 5 months ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7 + IL-23) and SPY230 (TL1A + IL-23) investig... Full story

Yahoo Finance • 6 months ago

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammato... Full story

Yahoo Finance • 6 months ago

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational th... Full story

Yahoo Finance • 6 months ago

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational th... Full story

Yahoo Finance • 6 months ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational th... Full story

Yahoo Finance • 6 months ago

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for... Full story

Yahoo Finance • 7 months ago

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational t... Full story

Yahoo Finance • 8 months ago

The Math Shows SCHA Can Go To $31

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 8 months ago

Spyre Therapeutics GAAP EPS of -$0.49 beats by $0.28

* Spyre Therapeutics press release [https://seekingalpha.com/pr/20190026-spyre-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate] (NASDAQ:SYRE [https://seekingalpha.com/symbol/SYRE]): Q2 GAAP EPS of -$0.49... Full story